Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-Center, Phase 1/2, Open-Label Study of Selinexor (KPT- 330), Lenalidomide, and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma

NCT02389543 is registered in ClinicalTrials.gov with Karyopharm Therapeutics Inc as lead sponsor.

NCT NCT02389543
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02389543 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-Center, Phase 1/2, Open-Label Study of Selinexor (KPT- 330), Lenalidomide, and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma
Lead sponsor
Karyopharm Therapeutics Inc
Phase
Phase 1/2
Overall status
Withdrawn
Start date
July 31, 2015
Completion date
February 28, 2018
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma